Osilodrostat (LCI699)结构式
|
常用名 | Osilodrostat (LCI699) | 英文名 | Osilodrostat |
---|---|---|---|---|
CAS号 | 928134-65-0 | 分子量 | 227.237 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 433.8±45.0 °C at 760 mmHg | |
分子式 | C13H10FN3 | 熔点 | N/A | |
MSDS | N/A | 闪点 | 216.2±28.7 °C |
Osilodrostat (LCI699)用途Osilodrostat (LCI699) 是人11β-羟化酶和醛固酮合成酶的有效抑制剂,IC50分别值为2.5 和0.7nM。 |
中文名 | Osilodrostat |
---|---|
英文名 | 4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzo nitrile |
英文别名 | 更多 |
描述 | Osilodrostat (LCI699) 是人11β-羟化酶和醛固酮合成酶的有效抑制剂,IC50分别值为2.5 和0.7nM。 |
---|---|
相关类别 | |
靶点 |
IC50: 2.5 nM (human 11β-hydroxylase), 0.7 nM (aldosterone synthase)[1] |
体内研究 | Osilodrostat和pasireotide单一疗法与垂体和肾上腺,肝脏和卵巢/输卵管的组织学和平均重量的显着变化相关。 Osilodrostat单独与肾上腺皮质肥大和肝细胞肥大有关。结合使用,osilodrostat/pasireotide不会加剧任何靶器官的变化,并改善单药治疗后观察到的肝脏和肾上腺变化。 osilodrostat和pasireotide的Cmax和AUC0-24h以近似剂量成比例的方式增加[1]。 Osilodrostat治疗可降低库欣病患者的尿中游离皮质醇;在第22周,78.9%的患者尿液游离皮质醇正常。用osilodrostat治疗通常耐受性良好[2]。 |
动物实验 | 大鼠:将60只雄性大鼠和60只雌性大鼠随机分为单性别组,每日服用帕瑞肽(0.3mg / kg /天,皮下注射),osilodrostat(20mg / kg /天,口服),osilodrostat / pasireotide组合(低剂量,1.5 / 0.03毫克/千克/天;中剂量,5 / 0.1毫克/千克/天;或高剂量,20 / 0.3毫克/千克/天),或载体13周[1]。 |
参考文献 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 433.8±45.0 °C at 760 mmHg |
分子式 | C13H10FN3 |
分子量 | 227.237 |
闪点 | 216.2±28.7 °C |
精确质量 | 227.085876 |
PSA | 41.61000 |
LogP | 1.13 |
外观性状 | 粉末 |
蒸汽压 | 0.0±1.0 mmHg at 25°C |
折射率 | 1.664 |
储存条件 | -20℃ |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
~% Osilodrostat (L... 928134-65-0 |
文献:Meredith, Erik L.; Ksander, Gary; Monovich, Lauren G.; Papillon, Julien P. N.; Liu, Qian; Miranda, Karl; Morris, Patrick; Rao, Chang; Burgis, Robin; Capparelli, Michael; Hu, Qi-Ying; Singh, Alok; Rigel, Dean F.; Jeng, Arco Y.; Beil, Michael; Fu, Fumin; Hu, Chii-Whei; Lasala, Daniel ACS Medicinal Chemistry Letters, 2013 , vol. 4, # 12 p. 1203 - 1207 |
Osilodrostat (LCI699)上游产品 5 | |
---|---|
Osilodrostat (LCI699)下游产品 0 |
osilodrostat |
4-(quinolin-3-ylmethyl-amino)-benzenesulfonamide |
Novartis LCI699 |
(R)-4-(6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile |
UNII-5YL4IQ1078 |
4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile |
Benzonitrile, 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluoro- |
3-<N-(4'-Amidosulfonylphenyl)aminomethyl>quinoline |
4-((R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluoro-benzonitrile |